Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
67.96
-0.21 (-0.31%)
Mar 13, 2026, 4:00 PM EDT - Market closed
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover Tarsus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $89, which forecasts a 30.96% increase in the stock price over the next year. The lowest target is $51 and the highest is $105.
Price Target: $89 (+30.96%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Tarsus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 2 | 3 | 4 | 4 | 4 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 9 | 9 | 9 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $95 → $105 | Buy | Maintains | $95 → $105 | +54.50% | Feb 25, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $87 → $90 | Strong Buy | Maintains | $87 → $90 | +32.43% | Feb 25, 2026 |
| Barclays | Barclays | Buy Initiates $100 | Buy | Initiates | $100 | +47.15% | Dec 9, 2025 |
| Mizuho | Mizuho | Buy Initiates $100 | Buy | Initiates | $100 | +47.15% | Nov 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $84 → $87 | Strong Buy | Maintains | $84 → $87 | +28.02% | Nov 5, 2025 |
Financial Forecast
Revenue This Year
705.28M
from 451.36M
Increased by 56.26%
Revenue Next Year
892.00M
from 705.28M
Increased by 26.47%
EPS This Year
0.71
from -1.59
EPS Next Year
3.34
from 0.71
Increased by 373.33%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 750.6M | 951.0M | |||
| Avg | 705.3M | 892.0M | |||
| Low | 668.1M | 823.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 66.3% | 34.8% | |||
| Avg | 56.3% | 26.5% | |||
| Low | 48.0% | 16.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.37 | 4.95 | |||
| Avg | 0.71 | 3.34 | |||
| Low | -0.75 | 2.28 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 599.9% | |||
| Avg | - | 373.3% | |||
| Low | - | 223.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.